

## Partner search

**Company:** Kidopi

**Adress:**

Avenida Doutora Nadir Aguiar,  
1805

**Contact:** Mario Sergio Adolphi Junior

**Position:** CEO

**Telephone:** 16 98114 5928

**Email:** mario@kidopi.com.br

**More information :** (site, linkedin etc)

[www.kidopi.com.br](http://www.kidopi.com.br)

### Short Company presentation

(R & D guidelines, international activities, etc.)

Kidopi, founded in 2009, is a Brazilian-based company specializing in biomedical informatics. Its mission is to provide innovative, AI-driven health technology solutions that improve patient outcomes through customizable remote monitoring, risk evaluation, and outcome management. Their flagship product, CleverCare, uses artificial intelligence, natural language processing (NLP), and machine learning to provide personalized patient care both inside and outside of hospital environments. CleverCare has been implemented in leading healthcare institutions and pharmaceutical companies across Latin America.

**International Activities:** Kidopi is expanding internationally, with a specific focus on the **Spanish market**, particularly in the **oncology sector**. As part of this strategic direction, Kidopi aims to collaborate with leading healthcare institutions, such as **MD Anderson Cancer Center** in Spain. The company already has a successful partnership with **Hospital do Amor**, which is a collaborator of MD Anderson, and intends to leverage this relationship to strengthen its international presence and reach new markets.

### DESCRIPTION OF ITS TECHNOLOGY AND CAPABILITIES IN R & D

(Products, technologies, applications, services, etc.)

**CleverCare Overview:** CleverCare is Kidopi's flagship AI-driven platform, designed to support oncology patient management through remote monitoring and personalized care protocols. With a specific focus on **oncology**, CleverCare provides tailored solutions for cancer care, addressing the complex needs of

oncology patients both during and after treatment. By using advanced technologies like **Artificial Intelligence (AI)** and **Natural Language Processing (NLP)**, CleverCare enables healthcare providers to deliver continuous, personalized care and improve patient outcomes in the field of oncology.

### Key Features and Technologies for Oncology Care:

1. **Remote Monitoring for Oncology Patients:** CleverCare is particularly suited for oncology patients who require continuous monitoring and care during chemotherapy, radiation therapy, or post-surgical recovery. The platform allows healthcare providers to remotely track the patient's health status, symptoms, and treatment adherence, ensuring that any complications are detected early, thereby reducing hospital readmissions and emergency visits.
2. **Personalized Oncology Care Protocols:** Oncology care often involves highly individualized treatment plans, which CleverCare supports by allowing the creation of **customizable care protocols**. These protocols can be tailored to specific types of cancer, stages of disease, and treatment modalities (chemotherapy, radiotherapy, immunotherapy, etc.). CleverCare guides patients through their treatment journey by providing reminders, educational content, and symptom-checking prompts, all designed to enhance treatment adherence and patient engagement.
3. **Natural Language Processing (NLP) for Patient Communication:** Oncology patients can interact with CleverCare via familiar messaging platforms such as SMS, WhatsApp, and Telegram. Using **NLP**, CleverCare enables patients to communicate in natural language, describing their symptoms, concerns, or questions. The system interprets these messages and provides timely, personalized responses, making the interaction smooth and accessible for patients undergoing cancer treatment. NLP ensures that patients remain engaged without needing to navigate complex healthcare applications.
4. **AI-Driven Alerts and Feedback System:** CleverCare continuously monitors patient-reported outcomes and uses **AI** to evaluate the patient's progress. If deviations from expected recovery or treatment adherence are detected—such as worsening symptoms or missed treatments—the system automatically sends alerts to the oncology care team. This proactive feedback system enables quick intervention, ensuring that healthcare providers can address potential complications before they escalate.
5. **Oncology-Specific Outcome Tracking:** For oncology patients, tracking key health outcomes is critical for evaluating treatment success and managing long-term health. CleverCare supports the collection and analysis of **oncology-specific outcome measures**, such as treatment response, side effects, and quality of life indicators. These insights allow healthcare providers to make data-driven decisions, adjusting treatment plans based on real-time patient data.
6. **Integration with Oncology Departments and Systems:** CleverCare integrates seamlessly with oncology-specific systems such as **Electronic Medical Records (EMR)** and **hospital information systems**. This integration allows oncology departments to manage patient data efficiently, including treatment histories, lab results, and clinical notes, while maintaining a holistic view of the patient's progress throughout the cancer care continuum.

### Applications of CleverCare in Oncology:

- **Chemotherapy and Radiotherapy Monitoring:** CleverCare remotely monitors oncology patients undergoing chemotherapy or radiation therapy, tracking side effects, adherence to treatment schedules, and overall health status.
- **Post-Surgical Care for Cancer Patients:** Following cancer surgeries, such as mastectomies or tumor resections, CleverCare monitors patients to ensure proper recovery, detect post-operative complications, and prevent hospital readmissions.
- **Symptom and Side Effect Management:** CleverCare helps oncology patients manage side effects from treatments, such as fatigue, nausea, or pain, by providing timely interventions and symptom management protocols.
- **Long-Term Survivorship Care:** After completing active treatment, oncology patients still require ongoing care and monitoring. CleverCare facilitates long-term follow-up care, tracking recurrence risks, managing chronic conditions, and ensuring a high quality of life for cancer survivors.

### R&D Focus in Oncology:

Kidopi's R&D team is heavily focused on enhancing **CleverCare's oncology capabilities**, with ongoing efforts to refine AI models for more accurate **cancer risk prediction** and **outcome tracking**. The integration of **real-world evidence (RWE)** from oncology cases is a key area of research, as well as improving **NLP** to better understand patient-reported symptoms and quality of life indicators. Kidopi is also exploring collaborations with leading oncology institutions, such as MD Anderson Cancer Center, to validate and expand CleverCare's impact in oncology.

## PROPOSED COLLABORATIVE PROJECT IN R & D

(As much detail as possible, both in what it offers and what you want in a potential partner)

### Potential Benefits of the Collaboration:

- **For Kidopi:**
  - **Validation and Case Studies:** Through collaboration, Kidopi seeks to generate **real-world case studies** that validate the effectiveness of CleverCare in improving oncology patient outcomes. This will provide strong evidence to support the platform's capabilities in the oncology field and facilitate wider adoption by leading cancer care institutions.
  - **Enhanced AI Models:** By working with an oncology partner, Kidopi can refine its **AI and predictive analytics models** based on real patient data, improving their accuracy and effectiveness in detecting cancer-related risks and complications.
  - **Expanded International Presence:** A successful collaboration, particularly with a globally recognized institution, will strengthen Kidopi's presence in international markets, opening doors to partnerships with major oncology centers like **MD Anderson** and others.
  - **Research and Publications:** The collaboration will also result in joint research opportunities, leading to academic publications and contributions to the field of

AI-driven oncology care, further establishing Kidopi's reputation as an innovator in health technology.

- **For the Partner:**

- **Cutting-Edge AI-Driven Care:** The partner institution will benefit from access to cutting-edge AI technology that enhances the delivery of personalized, scalable oncology care, leading to better patient outcomes and operational efficiency.
- **Real-World Evidence (RWE):** The partner will gain insights from **real-world data analytics**, enabling them to evaluate and optimize oncology care **protocols** based on outcomes, treatment effectiveness, and patient satisfaction.
- **Cost-Effective Patient Monitoring:** By implementing CleverCare, the partner can improve post-treatment follow-up and long-term monitoring for oncology patients, reducing hospital readmissions, optimizing resource use, and improving quality of life for patients.
- **Research and Innovation Leadership:** The collaboration will position the partner institution as a leader in oncology innovation, as they will co-develop advanced AI-driven tools and contribute to ground-breaking research in personalized cancer care.

**Conclusion:** This proposed R&D collaboration offers a unique opportunity to co-develop, validate, and enhance AI-driven oncology care solutions that will revolutionize how cancer patients are monitored and managed. Kidopi's CleverCare platform, with its proven technology and scalability, combined with a partner's clinical expertise and patient population, will create a powerful synergy that drives significant advancements in oncology care.

**General comments:**

- By sending this information document authorizing its dissemination.
- Company webpage: [www.Kidopi.com.br](http://www.Kidopi.com.br)